Literature DB >> 19034657

Application of the glucose hydrogen breath test for the detection of bacterial overgrowth in patients with cystic fibrosis--a reliable method?

Arne R J Schneider1, Stefanie Klueber, Hans-Georg Posselt, Benjamin Funk, Lydia Murzynski, Wolfgang F Caspary, Juergen Stein.   

Abstract

Patients with cystic fibrosis (CF) have recently been deemed highly susceptible for bacterial intestinal overgrowth (BIO). We aimed to define the prevalence of BIO in children with CF by applying the H(2)-glucose breath test. Forty children with CF and ten healthy children received 1 g/kg D-glucose orally. Breath samples for H(2) content (ppm) were collected for 3 h. BIO was suspected if the breath hydrogen content increased by more than 20 ppm or if baseline concentrations topped 20 ppm. In 27 of 40 CF children (68%), breath hydrogen content exceeded 20 ppm. Whereas the breath hydrogen exhalation persisted above 20 ppm in almost all these children throughout the sampling period, none of the remaining children increased above this threshold. The high rate of CF children with elevated fasting hydrogen breath concentrations indicates that this phenomenon is less a sign of BIO rather than a consequence of global malabsorption and intestinal dysmotility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034657     DOI: 10.1007/s10620-008-0559-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

Review 1.  Standards of care for patients with cystic fibrosis: a European consensus.

Authors:  Eitan Kerem; Steven Conway; Stuart Elborn; Harry Heijerman
Journal:  J Cyst Fibros       Date:  2005-03       Impact factor: 5.482

Review 2.  Interactions between commensal bacteria and gut sensorimotor function in health and disease.

Authors:  Giovanni Barbara; Vincenzo Stanghellini; Giovanni Brandi; Cesare Cremon; Giovanni Di Nardo; Roberto De Giorgio; Roberto Corinaldesi
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

3.  Risk factors for small bowel bacterial overgrowth in cystic fibrosis.

Authors:  Jacqueline L Fridge; Carol Conrad; Lauren Gerson; Ricardo O Castillo; Kenneth Cox
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-02       Impact factor: 2.839

4.  Glucose-H2 breath test for small intestine bacterial overgrowth.

Authors:  G Corazza; M Sorge; A Strocchi; G Gasbarrini
Journal:  Gastroenterology       Date:  1990-01       Impact factor: 22.682

5.  Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.

Authors:  M Pimentel; E J Chow; H C Lin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

6.  Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node.

Authors:  E K Steffen; R D Berg; E A Deitch
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

7.  Serum immunoglobulin and soluble IL-2 receptor levels in small intestinal overgrowth with indigenous gut flora.

Authors:  S M Riordan; C J McIver; D Wakefield; M C Thomas; V M Duncombe; T D Bolin
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

8.  Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine.

Authors:  Oxana Norkina; Tim G Burnett; Robert C De Lisle
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 9.  Breath tests in the diagnosis of small intestine bacterial overgrowth.

Authors:  C E King; P P Toskes
Journal:  Crit Rev Clin Lab Sci       Date:  1984       Impact factor: 6.250

10.  Small-bowel bacterial overgrowth in the postgastrectomy syndrome.

Authors:  A Bjørneklett; O Fausa; T Midtvedt
Journal:  Scand J Gastroenterol       Date:  1983-03       Impact factor: 2.423

View more
  1 in total

Review 1.  Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Thomas Kelly; James Buxbaum
Journal:  Dig Dis Sci       Date:  2015-02-04       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.